Table 1.

Hydroxyproline:proline ratio by treatment group and organ in the TGF-β/CTGF synergy model

Organ	Control	Treatments
	-	TGF-β2	-	TGF-β2	TGF-β2
	-	-	CTGF	CTGF	CTGF
	-	-	-	-	FG-3019
Kidney	0.057 ± 0.001	0.061 ± 0.002	0.059 ± 0.001	0.094 ± 0.0051	0.085 ± 0.0031,3
Liver	0.015 ± 0.001	0.017 ± 0.001	0.016 ± 0.002	0.039 ± 0.0031	0.032 ± 0.0021,4
Lung	0.079 ± 0.002	0.078 ± 0.002	0.083 ± 0.001	0.088 ± 0.0012	0.083 ± 0.002,3
Heart	0.041 ± 0.001	0.044 ± 0.002	0.046 ± 0.002	0.055 ± 0.0021	0.053 ± 0.0031

Data shown represent mean ± SEM, n = 6 to 10.

¹P < 0.001, ²P < 0.01 compared with healthy control group, one way analysis of variance, Fisher's least significant difference.

³P < 0.05, ⁴P < 0.01 compared with transforming growth factor (TGF)-β2 and connective tissue growth factor (CTGF) coadministration group.